Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 11/9/20

11 months ago By Josh Neil
  • Share on

  • Facebook
  • Linkedin
Proventa International Weekly News

In the news this week, Oxford University and AstraZeneca have temporarily suspended their joint COVID-19 vaccine trials over safety fears as a subject falls ill. In other news, GSK and Sanofi begin their own COVID trials, and a group of pharma companies have established a pledge to ensure safety while developing coronavirus vaccines. 

ASTRAZENECA PAUSES COVID-19 TRIAL OVER SAFETY FEARS – AstraZeneca has suspended trials of its experimental COVID vaccine AZD1222 after one trial participant experienced an ‘unexplained illness’. The company noted that this was a routine suspension, though it will delay results of the trial in what is a close race to vaccine production. The news comes days after AstraZeneca announced it was expanding development of the vaccine into a phase III clinical trial in the U.S. to determine safety and efficacy.

GSK AND SANOFI BEGIN CORONAVIRUS TRIALS – GSK and Sanofi have begun clinical trials of their potential vaccine for COVID-19. The trial will see 440 individuals in the U.S. receive the vaccine, with results of the initial trials set for December 2020.

PHARMA COMPANIES ANNOUNCE ‘HISTORIC’ SAFETY PLEDGE FOR VACCINE PRODUCTION – Nine vaccine developers, including Merck and Pfizer, have taken part in a ‘historic pledge’ to uphold scientific and ethical standards while looking for a COVID-19 vaccine. This follows a number of debates about vaccine safety this year.

In other news:

R&D
AstraZeneca and Cancer Research UK pioneer antibody against cancer enzyme

Manufacturing
Inovio and Thermo Fisher Scientific sign deal for coronavirus vaccine production
CDC set to open vaccine sites by 1 November 2020

That’s all for now. See you next week!

Joshua Neil, Editor
Proventa International

To ensure you remain up-to-date on the latest in clinical development, sign up for Proventa International’s online Biomanufacturing Strategy Meeting 2020.

More news

COVID’s Impact on Innovations in Regulatory Affairs

While the impact of COVID-19 was significant in every area of the pharmaceutical sector, some of the most pandemic’s most overlooked impacts were within the regulatory space. From study design to submissions, the virus affected every aspect of drug regulation,...

3 weeks ago
Bioprocess,Clinical Development,Weekly Roundups

COVID’s Impact on Innovations in Regulatory Affairs

While the impact of COVID-19 was significant in every area of the pharmaceutical sector, some of the most pandemic’s most overlooked impacts were within the regulatory space. From study design to submissions, the virus affected every aspect of drug regulation,...

3 weeks ago

Latest Advancements in Parkinson’s Treatment: CGT Shows Potential to Reverse Disease

Every hour, two more people are diagnosed with Parkinson’s in the UK and the global patient population continues to rise. To date, there are no disease-modifying therapies available on the market for Parkinson's (PD) patients. Pharmaceutical company Bayer is simultaneously...

1 month ago
Bioprocess,Clinical Development,Weekly Roundups

Latest Advancements in Parkinson’s Treatment: CGT Shows Potential to Reverse Disease

Every hour, two more people are diagnosed with Parkinson’s in the UK and the global patient population continues to rise. To date, there are no disease-modifying therapies available on the market for Parkinson's (PD) patients. Pharmaceutical company Bayer is simultaneously...

1 month ago

Strategies Implemented for New Modalities of Therapeutic Targeting: ASOs and RNAi

In 2018, the FDA approved the first small interfering RNA (siRNA) drug, patisiran, to treat a disease known as hereditary transthyretin amyloidosis. Since then, an increasing number of oligonucleotide-based drugs have reached the market, showing advantages over small molecule drugs....

1 month ago
Bioprocess,Clinical Development,Weekly Roundups

Strategies Implemented for New Modalities of Therapeutic Targeting: ASOs and RNAi

In 2018, the FDA approved the first small interfering RNA (siRNA) drug, patisiran, to treat a disease known as hereditary transthyretin amyloidosis. Since then, an increasing number of oligonucleotide-based drugs have reached the market, showing advantages over small molecule drugs....

1 month ago
Working With us

Interested?
Reserve your space